Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;28(7):2300087.
doi: 10.2807/1560-7917.ES.2023.28.7.2300087.

Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022

Anne J Huiberts  1 , Brechje de Gier  1 , Christina E Hoeve  1 , Hester E de Melker  1 , Susan Jm Hahné  1 , Gerco den Hartog  2   1 , Janneke Hhm van de Wijgert  3   1 , Susan van den Hof  1 , Mirjam J Knol  1
Affiliations

Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022

Anne J Huiberts et al. Euro Surveill. 2023 Feb.

Abstract

We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18-59-year-olds and 14% in 60-85-year-olds. Protection of Omicron infection was higher than of bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalisations, we found limited added benefit in preventing SARS-CoV-2 infection.

Keywords: COVID-19; SARS-CoV-2; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1
Figure 1
14-day moving average of number of SARS-CoV-2 infections reported per 100,000 participants by age group, prior infection status and vaccination status, the Netherlands, 26 September–19 December 2022 (n = 32,542)
Figure 2
Figure 2
Relative vaccine effectivenessa and 95% confidence interval of bivalent COVID-19 vaccine overall and stratified by infection history and by age group, the Netherlands, 26 September 2022–19 December 2022 (n = 32,542)
Figure 3
Figure 3
Stratified and sensitivity analysesa for relative vaccine effectiveness of bivalent COVID-19 vaccination by age group, the Netherlands, 26 September 2022–19 December 2022 (n = 32,452)
See this image and copyright information in PMC

References

    1. World Health Organization (WHO). One year since the emergence of COVID-19 virus variant Omicron. Geneva: WHO; 2022. Available from: https://www.who.int/news-room/feature-stories/detail/one-year-since-the-...
    1. European Medicines Agency (EMA). First adapted COVID-19 booster vaccines recommended for approval in the EU. EMA; 2022. Available from: https://www.ema.europa.eu/en/news/first-adapted-covid-19-booster-vaccine...
    1. Rijksinstituut voor Volksgezondheid en Milieu (RIVM). Varianten van het coronavirus SARS-CoV-2.[Variants of the coronavirus SARS-CoV-2]. Bilthoven: RIVM; 2023. Dutch. Available from: https://www.rivm.nl/coronavirus-covid-19/virus/varianten
    1. Huiberts A, Kooijman M, de Melker H, Hahne S, Grobbee D, Hoeve C, et al. Design and baseline description of an observational population-based cohort study on COVID-19 vaccine effectiveness in the Netherlands - The VAccine Study COvid-19 (VASCO) [PREPRINT]. Research Square. 2022. 10.21203/rs.3.rs-1645696/v1 - DOI
    1. Huiberts AJ, de Gier B, Hoeve CE, de Melker HE, Hahné SJM, Hartog Gd, et al. Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from 12 July 2021 to 6 June 2022: a prospective cohort study [PREPRINT]. medRxiv. 2023:2023.01.09.23284335. 10.1101/2023.01.09.23284335 10.1101/2023.01.09.23284335 - DOI - DOI - PMC - PubMed